Disclosure of total number of voting rights and number of shares in the capital as of October 31, 2026

Pursuant to article L-223-8 II of the French "code de Commerce" and 223-16 of the AMF's General Regulations.

Total number of shares	**49,071,263**
Number of real voting rights* (excluding treasury shares**)	**48,997,986**
Theoretical number of voting rights* (including treasury shares**)	**49,048,063**

(*) Class E preference shares are non-voting
(**) pursuant to article 223-11 of the AMF's General Regulations

Furthermore, as of October 31, 2026, out of the 14,424,541 warrants (BSA) issued in connection with the 2025 capital increase, 12,261,125 remained outstanding and exercisable.

About Median Technologies: Pioneering innovative software as a medical device and imaging services, Median Technologies harnesses cutting-edge AI to enhance the accuracy of early cancer diagnoses and treatments. Median's offerings include iCRO, which provides medical image analysis and management in oncology trials, and eyonis®, an AI/ML tech-based suite of software as medical devices (SaMD). Median empowers biopharmaceutical entities and clinicians to advance patient care and expedite the development of novel therapies. The French-based company, with a presence in the U.S. and China, trades on the Euronext Growth market (ISIN: FR0011049824, ticker: ALMDT). For more information, visit www.mediantechnologies.com.

Contacts

Median Technologies
Emmanuelle Leygues
VP, Corporate Marketing & Financial Communications
+33 6 10 93 58 88
emmanuelle.leygues@mediantechnologies.com

Press – MAARC
Bruno Arabian
+33 6 87 88 47 26
bruno.arabian@maarc.fr

Investors – SEITOSEI ACTIFIN
Ghislaine Gasparetto
+33 6 85 36 76 81
ghislaine.gasparetto@seitosei-actifin.com